ArticleOncology letters2018
CDH2 expression is of prognostic significance in glioma and predicts the efficacy of temozolomide therapy in patients with glioblastoma.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Identification of Hub Genes in Idiopathic Pulmonary Fibrosis and Their Association with Lung Cancer by Bioinformatics Analysis.Advances in respiratory medicine · 2023Pooled it
- Image Feature Fusion of Hyperspectral Imaging and MRI for Automated Subtype Classification and Grading of Adult Diffuse Gliomas According to the 2021 WHO Criteria.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Article
- Personalized Driver Gene Prediction Using Graph Convolutional Networks with Conditional Random Fields.Biology · 2024Article
- Transcriptomics-based anti-tuberculous mechanism of traditional Chinese polyherbal preparation NiuBeiXiaoHe intermediates.Frontiers in pharmacology · 2024Article
- Glioblastoma Stem Cell Targeting Peptide Isolated Through Phage Display Binds Cadherin 2.Stem cells (Dayton, Ohio) · 2023Article
- Use of phage display biopanning as a tool to design CAR-T cells against glioma stem cells.Frontiers in oncology · 2023Article
- Dedifferentiated cells obtained from glioblastoma cell lines are an easy and robust model for mesenchymal glioblastoma stem cells studies.American journal of cancer research · 2023Article
- Phyllanthus taxodiifolius Beille Disrupted N-cadherin, Vimentin, Paxillin and Actin Stress Fibers in Glioblastoma.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Cadherin-3 is a novel oncogenic biomarker with prognostic value in glioblastoma.Molecular oncology · 2022Article
- hsa_circ_0000285 facilitates thyroid cancer progression by regulating miR-127-5p/CDH2.Journal of clinical laboratory analysis · 2022Article
- Substrate stiffness effect on molecular crosstalk of epithelial-mesenchymal transition mediators of human glioblastoma cells.Frontiers in oncology · 2022Article
- Identification and verification of the molecular mechanisms and prognostic values of the cadherin gene family in gastric cancer.Scientific reports · 2021Article
- High expression of oncogene cadherin-6 correlates with tumor progression and a poor prognosis in gastric cancer.Cancer cell international · 2021Article
- SPAG5 Is Involved in Human Gliomagenesis Through the Regulation of Cell Proliferation and Apoptosis.Frontiers in oncology · 2021Article
- The Subventricular Zone, a Hideout for Adult and Pediatric High-Grade Glioma Stem Cells.Frontiers in oncology · 2020Review
- Article
- Cdh4 Down-Regulation Impairs in Vivo Infiltration and Malignancy in Patients Derived Glioblastoma Cells.International journal of molecular sciences · 2019Article
- CDH2 gene rs11564299 polymorphism is a risk factor for knee osteoarthritis in a Chinese population: a case-control study.Journal of orthopaedic surgery and research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma is the most common and malignant primary brain cancer in adults. Radical surgical excision accompanied by radiotherapy and chemotherapy is the prevailing standard therapy for patients with glioblastoma (GBM). Cadherin 2 (CDH2) encodes the N-cadherin protein, a classical cadherin and a member of the cadherin superfamily, which sustains the integrity of the cell and is involved in several cell signal transduction pathways. In the present study, the association between CDH2 expression and clinical features was investigated based on the Chinese Glioma Genome Atlas (CGGA), the Rembrandt datasets and The Cancer Genome Atlas datasets (TCGA). Medical statistical methods, including Kaplan-Meier analysis and Cox regression model were used. The expression of CDH2 was identified to be strongly associated with glioma World Health Organization grade in the CGGA and Rembrandt datasets. Patients with low CDH2 expression had an improved prognosis and benefited from temozolomide therapy. In conclusion, these findings revealed that CDH2 may serve as a prognostic and predictive molecular biomarker for the grading and treatment of glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.